Rosuvastatin versus Atorvastatin in the treatment of Hypercholesterolaemia in African American Subjects(ARIES) - ARIES
Study identifier:4522US/0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin versus Atorvastatin in the treatment of Hypercholesterolaemia in African American Subjects. (ARIES)
Medical condition
Hypercholesterolemia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin
Sex
All
Actual Enrollment
1700
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2002
Primary Completion Date: -
Study Completion Date: 01 Mar 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Rosuvastatin | - |
| Active Comparator: 2 Atorvastatin | - |
Contacts
Investigators
Principal Investigator
Keith Ferdinand
Heartbeats Life Centre, New Orleans, USA
